TD Asset Management Inc. lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 38.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,254 shares of the medical device company’s stock after acquiring an additional 10,042 shares during the period. TD Asset Management Inc.’s holdings in DexCom were worth $1,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of DXCM. Advisor Group Inc. lifted its position in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares in the last quarter. IFP Advisors Inc lifted its position in DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in DexCom by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares in the last quarter. Finally, Balyasny Asset Management LLC purchased a new position in DexCom during the second quarter worth approximately $249,000.

Shares of DexCom, Inc. (NASDAQ DXCM) opened at $61.53 on Monday. DexCom, Inc. has a 1 year low of $42.62 and a 1 year high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

A number of equities analysts recently commented on DXCM shares. Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Piper Jaffray Companies reiterated an “overweight” rating and set a $78.00 price objective (down previously from $87.00) on shares of DexCom in a research report on Wednesday, August 16th. BidaskClub upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Tuesday, August 22nd. Finally, ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $70.69.

In related news, EVP Andrew K. Balo sold 6,490 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total value of $389,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $69.81, for a total value of $101,224.50. The disclosure for this sale can be found here. Insiders sold 34,710 shares of company stock worth $2,031,852 in the last 90 days. Company insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Shares Bought by TD Asset Management Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/dexcom-inc-dxcm-shares-bought-by-td-asset-management-inc/1756852.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.